Who is Dr. Marschall S. Runge and why is he retiring from the Board?

Dr. Marschall S. Runge is a member of Eli Lilly's Board of Directors. He has decided to retire from the Board effective August 31, 2024. The company stated that his decision to retire is voluntary and not due to any disputes or disagreements with Eli Lilly regarding its operations, policies, or practices.

Does this director change have any implications for Eli Lilly's financial performance or operations?

Based on the information provided in this 8-K filing, Dr. Runge's retirement is stated to be unrelated to any disagreements with the company. Therefore, it is unlikely to have immediate direct implications for Eli Lilly's ongoing financial performance or operational strategies. This appears to be a routine board succession event.

What is the significance of this 8-K filing for investors?

This 8-K filing serves as official notification to investors and the market about a change in the composition of Eli Lilly's Board of Directors. It confirms the departure of a director and clarifies that the departure is amicable, which is important for maintaining investor confidence in corporate governance and stability.

LLY 8-K: Leadership Changes

Summary

Eli Lilly & Company (LLY) has filed an 8-K report on August 16, 2024, primarily to announce a change in its Board of Directors. Dr. Marschall S. Runge has decided to retire from the Board, with his retirement effective August 31, 2024. The company explicitly states that this decision is not due to any disagreements concerning the Company's operations, policies, or practices. This is a standard procedural filing related to a director's departure.

Key Highlights

1Dr. Marschall S. Runge is retiring from Eli Lilly's Board of Directors.
2The retirement is effective August 31, 2024.
3Dr. Runge's departure is not related to any disagreements with the company.
4The company issued a press release on August 16, 2024, to announce this change.
5This filing is an 8-K report concerning a departure of a director.

ELI LILLY & Co 8-K Report, Executive Changes (Aug 16, 2024)

Summary

Key Highlights

Frequently Asked Questions